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Introduction: Plasma selenium (Se) concentrations are reduced in critically ill surgical patients, and lower plasma
Se concentrations are associated with worse outcomes. We investigated whether adjuvant Se supplementation in
the form of sodium selenite could improve outcomes in surgical patients with sepsis.
Methods: In this retrospective study, all adult patients admitted to a 50-bed surgical ICU with severe sepsis
between January 2004 and April 2010 were included and analysed according to whether they had received
adjuvant Se supplementation, which was given at the discretion of the attending physician. When prescribed,
Se was administered in the form of sodium selenite pentahydrate (Na2SeO3∙5H2O), in which 100 μg of Se
corresponds to 333 μg of sodium selenite. A bolus of sodium selenite corresponding to 1,000 μg of Se was
injected intravenously through a central venous line for 30 minutes, followed by infusion of 1,000 μg/day for
24 hours for 14 days until ICU discharge or death. We performed logistic regression analysis to investigate the
impact of adjuvant Se supplementation on hospital mortality.
Results: Adjuvant Se was administered to 413 (39.7%) of the 1,047 patients admitted with severe sepsis. Age and
sex were similar between patients who received adjuvant Se and those who did not. Compared with patients
who did not receive adjuvant Se supplementation, patients who did had higher scores on the Simplified Acute
Physiology Score II, a greater prevalence of cancer upon admission to the ICU and were more commonly admitted
after abdominal surgery. Compared with patients who did not receive adjuvant Se, patients who did had higher
hospital mortality rates (46% versus 39.1%; P = 0.027), and longer median (interquartile range (IQR)) ICU stays
(15 days (6 to 24) versus 11 days (4 to 24); P = 0.01) and hospital lengths of stay (33 days (21 to 52) versus 28 days
(17 to 46); P = 0.001). In multivariable analysis, adjuvant Se supplementation was not independently associated
with favourable outcome (odds ratio = 1.19, 95% confidence interval = 0.86 to 1.65; P = 0.288).
Conclusions: In this retrospective analysis of a large cohort of surgical ICU patients with severe sepsis, adjuvant
Se supplementation in the form of sodium selenite had no impact on in-hospital death rates after adjustment
for confounders.Introduction
Selenium (Se) is an important trace element in human
biology. It is of great importance in human health and
plays a key role in thyroid function, antioxidant defence
and immune function. Plasma Se levels are commonly
decreased in critically ill patients for several reasons, inclu-
ding decreased Se intake, haemodilution by resuscitation* Correspondence: yasser.sakr@med.uni-jena.de
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reproduction in any medium, provided the orfluids and incompletely replaced loss of biological fluids
that contain large quantities of trace elements (mainly
blood loss) [1,2]. In addition, Se requirements may increase
while a patient has inflammatory conditions, owing to the
increase in oxidative stress and production of reactive
oxygen species (ROS) [2,3].
Although adjuvant Se supplementation has been shown
to increase plasma selenoenzymes after 3 days [4,5],
controlled clinical trials in various groups of critically ill
patients [5-12] have failed to demonstrate a consistent. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gued that large concentrations of selenite may have
oxidant properties and may result in inhibition of nuclear
factor κB (NF-κB) to DNA binding [13,14] or a transient
proapoptotic action on inflammatory circulating cells
[15,16]. This effect has been hypothesised to attenuate the
excessive inflammatory response and explain the favou-
rable outcome in septic animals after receiving bolus
doses of sodium selenite [17,18]. A meta-analysis by the
Cochrane group [19] found no evidence to support use of
Se supplementation for primary or secondary prevention
of sepsis in critically ill patients. Authors of two other
recently published meta-analyses reported a trend toward
a reduction in the risk of death in patients receiving
Se supplementation [20,21]. We previously reported
that plasma Se concentrations were generally low in critic-
ally ill surgical patients and decreased considerably during
the ICU stay in patients with organ failure, especially
when lower SE concentration was attributed to infection
[1]. Lower plasma Se concentrations were also associated
with more tissue damage, the presence of infection or
organ dysfunction/failure and increased ICU mortality [1].
Se supplementation might thus be expected to have
some advantages in patients with severe sepsis. Indeed,
Angstwurm et al. [4] found that adjuvant treatment of
patients with high-dose sodium selenite might reduce
mortality rates in patients with severe sepsis or septic
shock, but these findings were not confirmed in a more
recent study in patients with systemic inflammatory re-
sponse syndrome (SIRS) and sepsis [12]. The influence of
case mix on the potentially beneficial effects of Se supple-
mentation in patients with severe sepsis is unknown, and
the impact of Se supplementation on outcomes in severe
sepsis patients in the postoperative setting has not previ-
ously been investigated.
The aim of our study was, therefore, to investigate
the possible impact of Se supplementation on out-
comes in patients with severe sepsis after major surgical
procedures.
Methods
The present study was approved by the Institutional
Review Board of Friedrich Schiller University Hospital,
Jena, Germany, and the need for informed consent was
waived because of the retrospective, anonymous nature
of the analysis. We retrospectively included all adult pa-
tients (>18 years old) admitted to our 50-bed surgical
ICU with severe sepsis between January 2004 and
April 2010. For patients admitted to the ICU more
than once, only the first admission was considered.
We excluded patients (n = 7) who were included in a
double-blind study in which the possible influence of
Se supplementation in patients with severe sepsis was
being investigated.Data collection
Data were collected from vital sign monitors, ventilators
and infusion pumps and automatically recorded using the
Computer Organized Patient Record Assistant data man-
agement system (COPRA System GmbH, Sasbachwalden,
Germany). This clinical information system provides staff
with complete electronic documentation, order entry (for
example, medications) and direct access to laboratory
results. Data recorded upon admission in this study
included age, sex, referring facility, primary and secondary
admission diagnoses, associated comorbidities and surgi-
cal procedures preceding admission. The presence of SIRS
criteria, organ failure and infection was recorded daily,
together with laboratory indices of organ dysfunction/fail-
ure and markers of tissue inflammation and infection. The
Simplified Acute Physiology Score II (SAPS II) [22] was
calculated at the time of admission, and the Sequential
Organ Failure Assessment (SOFA) score [23] was calcu-
lated daily using a special sheet by the physician in charge
of the patient. A plausibility check of the automatically
transmitted data was performed by the attending phys-
ician before the final scores were calculated. In sedated
patients, the Glasgow Coma Scale score before the initi-
ation of sedation was considered. Hospital mortality and
hospital discharge dates were available from the electronic
hospital records of all patients. In cases of clinically sus-
pected infection, blood cultures were obtained, together
with specimens from all relevant sites (bronchial aspirates,
urine, catheter tip, pleural and ascitic fluids), for microbio-
logical studies.
Nutritional support
Patients received artificial enteral or parenteral nutritional
support according to their clinical condition. Enteral for-
mulas used in our institution during the study period in-
cluded 100 μg of Se per day (Sondalis ISO; Nestlé Health
Science, Liverpool, UK) by continuous perfusion through
gastric or duodenal feeding tubes. Our target caloric in-
take was 25 kcal kg−1 (ideal body weight)/day, which was
achieved over the course of 2 to 3 days in all patients.
Additional micronutrient supplements included two vials
of electrolytes and multitrace elements (INZOLEN HK;
Dr F Köhler Chemie, Bensheim, Germany), each of
which contained 3.1 mg of Zn, 1.8 mg of Cu and
0.99 mg of Mn, as well as one vial of multivitamins
(Cernevit; Baxter Schweiz AG, Volketswil, Switzerland)
containing 3.5 mg of thiamine, 11.2 IU of vitamin E and
500 mg of vitamin C. Patients fed parenterally received a
multitrace element supplement (Tracitrans Plus AMP;
Fresenius Kabi AG, Bad Homburg, Germany) containing
105 μg of Se in the form of sodium selenite. The current
recommended dietary intake of Se in humans is between
55 and 75 μg per day [24]. The tolerable upper intake limit
of Se is defined as 300 μg per day [25].
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Severe sepsis and septic shock were diagnosed by the
attending senior intensivist according to the American
College of Chest Physicians/Society of Critical Care
Medicine Consensus Conference criteria [26]. As routine
procedure in our ICU, all patients are screened for the
presence of severe sepsis by qualified research nurses,
who confirm the diagnosis with the attending physicians.
A list of these patients is kept for research purposes.
The site of infection was documented in a special field
in the patient data management system and was con-
firmed retrospectively by a senior attending physician
(OB) for the purposes of this analysis.
Infection was defined on the basis of clinical history,
clinical symptoms, physical examination and laboratory
findings suggesting the presence of infection (a known
or strongly suspected source of infection with positive
bacterial culture for a pathogen or the presence of gross
pus in a closed space) that justified administration of anti-
infective therapy (excluding antimicrobial prophylaxis).
Microbiologically documented infection was defined as
infection supported by positive cultures of blood or body
fluid from a site of suspected infection. Clinically docu-
mented infection was defined as the presence of gross pus
or an abscess (confirmed anatomically and/or by imagery
and/or histological evidence), but no microbiological con-
firmation as cultures remained sterile because of ongoing
antibiotic therapy.
Organ failure was defined as a SOFA subscore >2
points for the corresponding organ. The maximum
SOFA score (SOFAmax) was defined as the highest SOFA
score reached during the ICU stay and the mean SOFA
score (SOFAmean) as the mean value throughout the
ICU stay.
Adjuvant selenium supplementation
Because of the lack of clear, universally accepted recom-
mendations about Se supplementation during the study
period, sodium selenite was prescribed in our unit at the
discretion of the attending physician within 24 hours of
the onset of severe sepsis. Pregnant women were not
considered as candidates for Se supplementation in our
ICU. When administered, Se was infused in the form of
sodium selenite pentahydrate (Na2SeO3∙5H2O), in which
100 μg of Se corresponds to 333 μg of sodium selenite
(Selenase T; Biosyn Arzneimittel, Fellbach, Germany). A
bolus of sodium selenite corresponding to 1,000 μg of Se
was injected intravenously through a central venous line
for 30 minutes, followed by infusions of 1,000 μg/day
over the course of 24 hours for 14 days until ICU
discharge or death. Adjuvant Se was not repeated in the
same patient during the ICU stay. Selenase T was
administered in accordance with the instructions of the
manufacturer. When preparing an infusion with Selenase Tsolution for injection as a supplement, the pH value must
not fall below 7.0 and the solution must not be mixed with
reducing substances (for example, vitamin C), as a precipi-
tate of elemental Se may result. The dosage of Se used in
our unit was chosen on the basis of efficacy shown in a
previous pilot study [27], and it corresponds to the dosage
recommended by the manufacturer for patients with sep-
sis. This dosage was also confirmed to be safe and effective
in patients with SIRS, sepsis and septic shock in a later
study [4].
Outcome parameter
The primary outcome parameter was in-hospital death.
Statistical analysis
The data were analysed using SPSS 17.0 for Windows
software (SPSS, Chicago, IL, USA). Discrete variables are
expressed as counts (percentage) and continuous variables
as means ± standard deviation (SD) or median and inter-
quartile range [IQR] unless stated otherwise. Categorical
data were compared using the χ2 test with Yates’s correc-
tion, Fisher’s exact test or the Cochran–Armitage trend
test, as appropriate. A Kolmogorov–Smirnov test was
used to verify the normality of distributions of continuous
variables. Continuous variables conforming to a normal
distribution were compared using Student’s t-test; other-
wise, the Mann–Whitney U test was applied.
To investigate the impact of Se supplementation on
hospital mortality after adjusting for differences in base-
line characteristics and severity of illness, we performed
logistic regression analysis with in-hospital death as the
dependent variable. Variables included in this analysis
were age, comorbid diseases, SAPS II scores upon ad-
mission, type of surgery, primary site of infection, SOFA
subscores and blood lactate levels on the day of onset of
severe sepsis. Collinearity between the variables (R2 > 0.7)
was checked prior to modelling, and none of the included
covariates were found to be collinear. A Hosmer–Leme-
show test for goodness of fit was performed, and odds
ratios (ORs) with 95% confidence intervals (CIs) were
computed. All statistics were two-tailed, and P < 0.05 was
considered to be statistically significant.
Results
Characteristics of the study groups
A total of 1,047 patients with severe sepsis were admit-
ted to our surgical ICU during the study period (mean
age = 67 years (±SD = 16); male = 67.4%). The character-
istics of the study group are shown in Table 1. The most
common surgical procedures in the whole cohort were
gastrointestinal (40.8%) and cardiothoracic (31.3%). The
most prevalent comorbidities upon admission to the
ICU were essential hypertension (41.8%), cancer (27.7%)
and insulin-dependent diabetes mellitus (25.4%). The most
Table 1 Characteristics of the cohorta
Characteristics All patients (N = 1,040) No selenium (n = 627) Selenium (n = 413) P-value
Age, (yr), mean ± SD 67 ± 16 67 ± 17 67 ± 14 0.685
Male, n (%) 701 (67.4) 416 (66.3) 285 (69.0) 0.371
Severity scores, mean ± SD
SAPS II, mean ± SD 48.9 ± 17.3 47.7 ± 17 50.8 ± 17.7 0.001
SOFA, mean ± SD 8.2 ± 3.5 8.2 ± 3.6 8.2 ± 3.4 0.732
Type of surgery, n (%)
Gastrointestinal 424 (40.8) 204 (32.5) 220 (53.3) <0.001
Cardiothoracic 326 (31.3) 228 (36.4) 98 (23.7) <0.001
Trauma 48 (4.6) 35 (5.6) 13 (3.1) 0.067
Others 242 (23.3) 160 (25.5) 82 (19.9) 0.3
Comorbidities, n (%)
Arterial hypertension 435 (41.8) 259 (41.3) 176 (42.6) 0.676
Diabetes mellitus 264 (25.4) 153 (24.4) 111 (26.9) 0.37
Cancer 288 (27.7) 154 (24.6) 134 (32.4) 0.005
Cirrhosis 71 (6.8) 39 (6.2) 32 (7.7) 0.339
Chronic renal failure 135 (13) 79 (12.6) 56 (13.6) 0.652
Source of sepsis, n (%)
Respiratory 445 (42.8) 315 (50.2) 130 (31.5) <0.001
Gastrointestinal 430 (41.3) 206 (32.9) 224 (54.2) <0.001
Cardiothoracic 47 (4.5) 32 (5.1) 15 (3.6) 0.264
Wound 33 (3.2) 19 (3.0) 14 (3.4) 0.746
Urogenital 23 (2.2) 12 (1.9) 11 (2.7) 0.421
Bloodstream 11 (1.1) 6 (1.0) 5 (1.2) 0.761
Catheter 8 (0.8) 7 (1.1) 1 (0.2) 0.156
No focus identified 2 (0.2) 1 (0.2) 1 (0.2) 1.000
CNS 4 (0.4) 2 (0.3) 2 (0.5) 0.652
Others 37 (3.6) 27 (4.3) 10 (2.4) 0.108
aCNS: Central nervous system; SAPS II: Simplified Acute Physiology Score II; SD: Standard deviation; SOFA: Sequential Organ Failure Assessment.
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abdominal (41.3%).
Adjuvant selenium supplementation
Se was used as an adjuvant therapy in 413 (39.7%) of the
1,047 patients. The median duration of adjuvant Se supple-
mentation was 8 days (IQR = 4 to 12). The characteristics
of the patients according to adjuvant Se supplementation
are shown in Table 1. Age and sex were similar in patients
who received Se and those who did not; however, patients
who received adjuvant Se supplementation had higher
SAPS II scores (50.8 vs. 47.7; P = 0.001) and a higher preva-
lence of cancer upon admission to the ICU (32.4% vs.
24.6%; P = 0.005), and they were more commonly admitted
to the ICU after abdominal surgery (53.3% vs. 32.5%;
P < 0.001) and less commonly after cardiothoracic surgery
(23.7% vs. 36.4%; P <0.001). Abdominal sepsis (54.2% vs.
32.9%; P < 0.001) was more prevalent and respiratory tractinfections were less prevalent (31.5% vs. 50.2%; P < 0.001)
in the Se group than in the other patients.
The parameters of inflammation and organ function
on the day of onset of severe sepsis are shown in Table 2.
C-reactive protein, procalcitonin and blood lactate levels
were higher in the Se group than in the other patients.
Serum creatinine, platelet count, haemoglobin level and
serum bilirubin level were similar between the two groups.
The median mean arterial pressure (IQR) was slightly
lower (59 mmHg (51 to 64) vs. 61 mmHg (55 to 67)) and
the median heart rate (IQR) was higher (113 beats/min
(96 to 134) vs. 108 beats/min (94 to 124)) in patients who
received adjuvant Se supplementation compared to those
who did not.
Morbidity and mortality
The overall ICU and hospital mortality rates were 31.3%
and 41.8%, respectively (Table 3). The median ICU and
Table 2 Physiological parameters at the onset of severe sepsisa
Physiological parameters All patients (N = 1,040) No selenium (n = 627) Selenium (n = 413) P-value
Leucocyte count, ×103/μl 14 (8.25 to 20.3) 14.3 (9.1 to 20.2) 13.5 (6.0 to 20.7) 0.059
C-reactive protein, mg/L 101 (19 to 210) 78 (13 to 193) 146 (46 to 235) <0.001
Procalcitonin, ng/ ml 2.7 (0.8 to 9.4) 2.3 (0.7 to 7.2) 3.7 (0.9 to 12.9) <0.001
Blood lactate, mg/dl 2.7 (1.6 to 5.4) 2.5 (1.6 to 5.3) 2.9 (1.7 to 5.6) 0.031
Mean arterial pressure, mmHg 60 (54 to 66) 61 (55 to 67) 59 (51 to 64) 0.006
Heart rate, beats/min 110 (95 to 127) 108 (94 to 124) 113 (96 to 134) 0.003
Serum creatinine, μmol/L 102 (75 to 152) 101 (75 to 146) 108 (74 to 166) 0.257
Platelet count, ×103/μl 178 (112 to 261) 176 (111 to 260) 179 (113 to 274) 0.854
Haemoglobin, mmol/L 5.5 (4.7 to 6.3) 5.5 (4.7 to 6.3) 5.5 (4.8 to 6.2) 0.757
Serum bilirubin, mg/dl 16 (10 to 27) 16 (11 to 27) 15 (10 to 28) 0.283
aData presented are median (25% to 75% interquartile range).
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30 days (IQR = 19 to 50), respectively. The ICU mortality
rates were similar between the two study groups (Se vs.
no Se: 33.9% vs. 29.5%; P = 0.135). Patients who received
adjuvant Se supplementation had higher hospital mortal-
ity rates (46% vs. 39%; P = 0.027) and longer stays in the
ICU (median = 15 days (IQR = 6 to 24) vs. 11 days (4 to
24); P = 0.01) and in-hospital (median = 33 days (IQR =
21 to 52) vs. 28 days (17 to 46); P = 0.001) than those who
did not. SOFAmax and SOFAmean scores during the ICU
stay were also higher in the Se patient group than in other
patients. None of the deaths of patients who received
sodium selenite in our study were attributable to Se
administration. In a multivariable analysis with in-hospital
death as the dependent variable, adjuvant Se supplemen-
tation was not independently associated with worse
outcome (OR = 1.19, 95% CI = 0.86 to 1.65; P = 0.288)
after adjustment for age, sex, SAPS II score, type of sur-
gery, comorbidities, focus of sepsis, SOFA subscores and
blood lactate levels at the onset of severe sepsis (Table 4).
Discussion
The main finding of our retrospective study is that
adjuvant Se supplementation had no impact on hospital
mortality, after adjustment for possible confounders inTable 3 Morbidity and mortalitya
Statistics All patients (N = 1,040)
SOFA score, mean ± SD
SOFAmean 7.9 (6.0 to 10.4)
SOFAmax 12 (10 to 15)
ICU mortality, n (%) 325 (31.3)
Hospital mortality, n (%) 435 (41.8)
ICU LOS (days), median (IQR) 13 (5 to 24)
Hospital LOS (days), median (IQR) 30 (19 to 50)
aIQR: Interquartile range; LOS: length of stay; SOFA: Sequential Organ Failure Assess
SOFAmean: Mean Sequential Organ Failure Assessment score.multivariable analysis, in a large cohort of patients with
severe sepsis admitted to our ICU over a 6-year period.
Patients who received adjuvant Se supplementation in
our study had higher hospital mortality rates and longer
ICU and hospital lengths of stay, likely because they
were more severely ill as evidenced by the higher SAPS
II scores upon admission to the ICU, the higher preva-
lence of cancer and the greater degree of tissue inflam-
mation and hypoperfusion compared to those who did
not receive adjuvant Se. Indeed, after adjustment for
possible confounders, adjuvant Se supplementation was
not independently associated with an increased risk of
in-hospital death.
Se is an essential trace element that has antioxidant,
regulatory and immune functions. Glutathione peroxidase
(GPx), one of the main Se-containing enzymes, maintains
membrane integrity and reduces the likelihood of pro-
pagation of oxidative damage to biomolecules through
reduction of inorganic and organic peroxides [28,29]. Sele-
noprotein P is the most prevalent selenoprotein in plasma
and has been proposed to be the most important marker
of Se deficiency in sepsis [17], which supports arguments
against the role of GPx as an antioxidant in plasma in the
absence of glutathione in this compartment. We previ-
ously reported that plasma Se levels were lower than theNo selenium (n = 627) Selenium (n = 413) P-value
7.6 (5.7 to 10.3) 8.3 (6.3 to 10.5) 0.002
12 (9 to 14) 13 (11 to 15) <0.001
185 (29.5) 140 (33.9) 0.135
245 (39.1) 190 (46.0) 0.027
11 (4 to 24) 15 (6 to 24) 0.01
28 (17 to 46) 33 (21 to 52) 0.001
ment; SOFAmax: Maximum Sequential Organ Failure Assessment score;
Table 4 Summary of multivariable logistic regression analysis with in-hospital death as the dependent variablea
Variables Univariate analysis Multivariable analysis
OR (95% CI) P-value OR (95% CI) P-value
Adjuvant selenium 1.33 (1.03 to 1.71) 0.027 1.19 (0.86 to 1.65) 0.288
Age (per year) 1.03 (1.02 to 1.71) <0.001 1.02 (1.01 to 1.04) 0.001
Sex 1.46 (0.95 to 1.65) 0.005 1.20 (0.88 to 1.65) 0.249
SAPS II score 1.09 (1.03 to 1.18) <0.001 1.02 (1.01 to 1.03) 0.003
Type of surgery
Gastrointestinal 2.19 (0.79 to 2.42) <0.001 0.05 (0.24 to 1.04) 0.065
Cardiothoracic 0.68 (0.53 to 1.25) <0.001 0.36 (0.18 to 0.75) 0.006
Trauma 1.16 (0.68 to 3.08) 0.224 0.61 (0.23 to 1.61) 0.321
Others 0.64 (0.5 to 0.85) 0.008 0.44 (0.21 to 0.93) 0.031
Comorbidities
Arterial hypertension 0.88 (0.05 to 1.22) 0.369 1.02 (0.75 to 1.38) 0.926
Diabetes mellitus 0.93 (0.04 to 2.55) 0.621 0.77 (0.55 to 1.08) 0.129
Cancer 2.35 (1.76 to 3.06) <0.001 2.12 (1.50 to 2.99) <0.001
Cirrhosis 1.27 (1.07 to 2.57) <0.001 2.63 (1.40 to 4.94) 0.037
Chronic renal failure 1.30 (1.29 to 1.75) 0.160 1.62 (1.03 to 2.55) 0.037
Source of sepsis
Respiratory 0.96 (0.53 to 1.12) <0.001 0.88 (0.40 to 1.91) 0.738
Gastrointestinal 1.02 (0.99 to 2.47) <0.001 1.64 (0.73 to 3.67) 0.227
Cardiothoracic 0.99 (0.58 to 1.00) 0.090 1.01 (0.35 to 2.91) 0.985
Wound 0.99 (0.60 to 1.01) 0.177 0.59 (0.19 to 1.85) 0.362
Urogenital 0.997 (0.38 to 1.0) 0.057 0.32 (0.08 to 1.2) 0.090
Bloodstream 1.02 (1.01 to 1.16) 0.806 1.54 (0.34 to 6.86) 0.574
SOFA subscores (per point)
SOFA resp 0.89 (0.46 to 1.08) 0.053 1.01 (0.91 to 1.13) 0.807
SOFA coag 1.26 (0.87 to 1.44) 0.001 1.18 (0.99 to 1.4) 0.063
SOFA liver 1.78 (1.44 to 3.1) 0.001 1.18 (0.98 to 1.40) 0.075
SOFA CVS 1.09 (0.90 to 1.87) 0.060 1.00 (0.89 to 1.12) 0.995
SOFA CNS 1.92 (1.02 to 3.19) 0.631 0.97 (0.86 to 1.08) 0.531
SOFA ren 1.26 (0.28 to 1.32) <0.001 1.14 (0.96 to 1.35) 0.148
Blood lactate (mg/dl) 1.08 (0.88 to 1.09) <0.001 1.07 (1.03 to 1.12) 0.002
aCI: Confidence interval; CNS: Central nervous system; coag: Coagulation; CVS: Cardiovascular system; OR: Odds ratio; ren: Renal; resp: Respiration; SAPS II:
Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment.
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ill patients admitted to a surgical ICU [1]. Lower plasma
Se levels were associated with higher degrees of tissue
damage, the presence of infection and/or organ dys-
function/failure and increased ICU mortality. It has
been argued that large concentrations of selenite may have
oxidant properties and may result in inhibition of NF-κB
to DNA binding through direct oxidation of the thiol
groups of this transcription factor [13,14] or in transient
proapoptotic action on inflammatory circulating cells
[15,16]. This effect has been hypothesized to attenuate
the excessive inflammatory response and explain the
favourable outcomes in septic animals that received bolusdoses of sodium selenite [17,18]. Experimental evidence of
this possible mechanism of action of sodium selenite is
based on studies in which researchers used higher, rather
toxic, doses of sodium selenite [13-16,30]. Those studies
were performed largely in the context of cancer research
[13,15,16,30], not in severe sepsis. Wang et al. reported
that the administration of a large bolus of sodium selenite
(2,000 μg), rather than continuous administration, resulted
in a better haemodynamic profile, fewer sepsis-induced
microvascular alterations and prolonged survival time in a
sheep model of peritonitis [18]. They did not observe sig-
nificant differences in lipid peroxidation among the study
groups at any time, however, so their results provide no
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mechanism [31,32]. Interestingly, although the bolus dos-
age of sodium selenite in the study by Wang et al. was
about five times higher than the dosage used in our study
(0.08 mg/kg vs. 0.015 mg/kg), they reported no toxicity
due to sodium selenite [18].
The antioxidant and oxidant mechanisms of action of
sodium selenite both offer a plausible rationale for the
use of this compound in patients with severe sepsis. In
our analysis, however, we could not confirm that adju-
vant Se supplementation improved outcomes in terms of
in-hospital mortality in a nonselected group of patients
with severe sepsis undergoing major surgical procedures.
Several theories may be used to explain our findings.
Although adjuvant Se supplementation may positively
influence the antioxidant capacity and immune response
in patients with severe sepsis [4,5,12,27,33], it may not
have any direct influence on the evolution of postope-
ative complications and their deleterious effects on out-
come. Previous researchers [4,10,12,34] who investigated
the possible impact of adjuvant Se supplementation in
patients with severe sepsis included mixed medical and
surgical ICU patients (12.5% to 39.7% surgical), so the
results of those studies cannot be extrapolated to surgical
ICU patients.
The dose of adjuvant Se may also have influenced the
results of our study. We used the dose employed by
Angstwurm et al. [4], which has been shown to restore
Se and GPx levels to normal values. However, the opti-
mal dosage of Se has not been defined in a pure surgical
case mix, in which Se losses may also occur during
surgical procedures or via loss of body fluids through
surgical drains. Higher doses of Se than those given to
our patients may be required for Se supplementation to
have a positive impact on outcomes in surgical ICU
patients. Forceville et al. [10] proposed administration of
high doses of Se (4,000 μg on the first day and 1,000 μg/
day thereafter) as adjuvant therapy in patients with
septic shock. Although those authors were not able to
elucidate a beneficial effect of that dosage of Se on
outcomes, probably because of the small sample size
(n = 60), no obvious toxicity was attributable to the high
Se dose. In another study involving patients with SIRS
[5], a bolus loading dose of selenite delivering 2,000 μg
of Se, followed by a continuous intravenous infusion of
1,600 μg/d for 10 days, was most effective at returning
serum Se to physiologic levels and safely maximizing
GPx activity. Likewise, in 150 patients with SIRS and/or
sepsis, Valenta et al. [12] reported that a high dose of
adjuvant Se supplementation (1,000 μg on the first day
and 1,500 μg/day on days 2 to 14) increased plasma Se
and GPx levels, but did not reduce mortality.
In contrast to our findings, researchers in several small
studies [27,34,35] have reported beneficial effects of Sesupplementation in heterogeneous groups of critically ill
patients with acute pancreatitis [36] or SIRS [27,35] in
terms of improved survival [36] or decreased frequency
and severity of multiple organ failure [27]. Likewise, in a
large, multicentre, randomized controlled trial comprising
189 patients with severe sepsis, adjuvant Se supplemen-
tation at a dosage similar to that used in our study was
associated with reduced 28-day mortality (42.4% in the Se
supplementation group vs. 56.7% in patients in the
placebo group) [4], although the beneficial effects of
Se supplementation on outcomes were observed only in
the per-protocol group and not in the intention-to-treat
analysis [4]. The discrepancies between the results of these
studies [4,27,35,36] and ours may be attributed to dif-
ferences in case mix. Our data suggest that surgical ICU
patients with severe sepsis may not benefit from adjuvant
Se supplementation, at least at the dosage used in our
study. Future prospective, randomized studies are required
to support or refute this assumption.
Selenocompounds are known to be toxic, at least in
part due to their oxidant properties at high dosages [37].
The dosage of sodium selenite administered in our study
has been shown in several previous studies to be safe
and well-tolerated by critically ill patients [4,27]. Although
the degree of organ dysfunction and/or failure during the
ICU stay, as assessed by SOFA scores, was higher in
patients who received sodium selenite in our study, it can
be attributed to the differences in organ function already
present at the time of onset of severe sepsis and before
sodium selenite administration. None of the deaths of
patients who received sodium selenite in our study were
attributable to drug administration. This result suggests
that sodium selenite, at least at the dosage applied in our
study, does not have relevant acute toxic manifestations.
Nonetheless, as the manifestations of sodium selenite
toxicity are similar to those of sepsis-associated organ fail-
ure and may be additionally masked in sedated patients,
animal studies are warranted to define safety margins
regarding sodium selenite dosages. We also cannot ela-
borate on long-term toxicity because of the retrospective
nature of the study.
To the best of our knowledge, our present study is the
largest to date in which the possible impact of Se supple-
mentation in critically ill patients with severe sepsis after
major surgery has been investigated. However, our analysis
has some limitations. First, the retrospective nature of the
study and the absence of precise criteria upon which to
establish the indications for Se supplementation during
the study period may have introduced bias-by-indication
because Se was given only to the more severely ill patients.
Second, the multivariate analysis is limited by the included
variables because of the retrospective nature of the study
and the results not being adjusted for other, unmeasured
variables that might have had an impact on outcomes,
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in individual patients and the septic events preceding
admission to the ICU. Another possible confounding
factor that was not considered in our study is the time of
onset of sepsis. Also, the results of our analysis may not
be extrapolated to other ICU patients, such as medical
patients.
Conclusion
In this retrospective analysis of a large cohort of surgical
ICU patients with severe sepsis, adjuvant Se supplemen-
tation in the form of sodium selenite had no impact on
in-hospital death rates after adjustment for possible
confounders.
Key messages
 Se is an important trace element in human biology.
 Se is of great importance in human health and plays
a key role in thyroid function, antioxidant defence
and immune function.
 Sodium selenite may elucidate both antioxidant and
oxidant effects in severe sepsis, either or both of
which may explain its potentially favourable effect
on patient outcomes.
 In our large cohort of surgical ICU patients with
severe sepsis, adjuvant Se supplementation in the
form of sodium selenite had no impact on
in-hospital death rates after adjustment for
confounders.
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